Merlin, encoded by the Neurofibromatosis 2 (NF2) gene, is a multifunctional tumor suppressor that integrates and regulates extracellular cues and intracellular signaling pathways, both at the plasma membrane and in the nucleus, to control cell proliferation, migration and invasion. Molecular mechanisms regulating merlin's tumor-suppressive activity have not been clearly defined. Here we report that merlin can be sumoylated on Lysine residue (K76) in vitro and in vivo. Sumoylation mediates merlin's intramolecular and intermolecular binding activities and regulates its cytoplasm/nucleus trafficking. Interestingly, sumoylation of merlin is regulated by its phosphorylation via Akt and PAK2 kinases. Mutation of K76 into arginine (R) abolishes its sumoylation, disrupts merlin cortical cytoskeleton residency and attenuates its stability. Using a K76R mutant merlin in a subcutaneous U87MG xenograft model, we demonstrate that merlin sumoylation is required for tumor-suppressive activity. Taken together, our findings indicate that merlin is sumoylated and that this post-translational modification is essential for tumor suppression.
INTRODUCTION
Neurofibromatosis type 2 (NF2) is an autosomal-dominant inherited tumor predisposition syndrome caused by mutations in the NF2 gene on chromosome 22 . 1 Merlin is the product of NF2 gene, which was discovered as a tumor suppressor that is inactivated in NF2 almost two decades ago. 2, 3 Deficiency of merlin leads to the development of benign tumors of the nervous system such as schwannomas and meningiomas. Merlin belongs to the band 4.1 family of cytoskeleton-associated proteins that link cell surface glycoproteins to the actin cytoskeleton. 4 It is a 595-amino acid protein composed of three predicted structural domains: an N-terminal domain (NTD/FERM domain), a predicted a-helix region and a C-terminal domain (CTD). 2, 3 The N-terminal domain (NTD/ FERM domain) contains the highly conserved sequences found in other ERM (Ezrin/Radixin/Moesin) proteins important for interactions with cell surface glycoproteins including CD44 and intercellular adhesion molecules. 5, 6 Merlin mediates it's tumorsuppressive effect by directly modulating a variety of mitogenic pathways such as Rac-PAK signaling, 7, 8 activation of mTORC1 signaling, 9 ,10 the EGFR-Ras-ERK pathway, 11, 12 the PI3K-Akt pathway 13 and FAK-Src signaling. 14 Through these pathways, merlin regulates neoplastic properties by inhibiting cell proliferation, 15 migration 16 and invasion.
14 Growth suppression by merlin is dependent on its ability to form a productive N-terminal/C-terminal association. 17, 18 In this regard, merlin exists in 'open' (inactive form) and 'closed' (active form) conformations, which are regulated by a physical intramolecular interaction between the N-and C termini. [19] [20] [21] Merlin S518 is phosphorylated by p21-activated kinases (PAKs), which affects the intramolecular interaction and changes conformation. [22] [23] [24] We have also demonstrated that Akt directly binds and phosphorylates merlin on residues T230 and S315. Furthermore, Akt-mediated phosphorylation leads to merlin degradation by polyubiquitination. 25 In addition to its plasma membrane residency, recent studies have indicated that the closed form of merlin can reside in the nucleus, bind to the E3 ubiquitin ligase CRL4 DCAF1 and inhibit its activity, which contribute to merlin tumor suppressor activity. 26 Sumoylation is a post-translational modification characterized by covalent binding of small ubiquitin-like modifier (SUMO) to a target protein. 27, 28 It is a reversible modification that affects target protein functions such as subcellular localization, protein partnering, DNA binding, regulation of transcription factors and control of protein stability. 29, 30 For example, SUMO modification of p53 represents an additional regulatory step that alters its protein stability and may contribute to activation of the p53 response. 31 A short sequence containing the consensus C-Lys-X-Asp/Glu (where lysine is the modified amino acid, C is a large hydrophobic residue and X is any amino acid residue) is thought to be necessary for proteins to be sumoylated. 28 In the present study, we show that merlin can be sumoylated in vitro and in vivo and demonstrate that the Lysine 76 residue is the major sumoylation site. Mutation of K76 into R causes retention of merlin within the cytoplasm and reduces protein stability, significantly inhibiting merlin's suppressor activities on schwannoma cells proliferation, migration and invasion. Further, K76R mutation reduces its inter-and intra-molecular binding activities. Moreover, we demonstrate that Akt or PAK phosphorylation is necessary for merlin sumoylation. Collectively, our studies demonstrate that merlin sumoylation has an important role in regulating its tumor suppressor activities, which is essential not only for understanding the physiological functions of merlin but also for the future development of novel drug treatments for merlin-related disease.
wild-type SUMO1 but not mutated SUMO1 (Figure 1a , right panels). As a positive control, p53 was also markedly sumoylated by wild-type but not mutated SUMO1 (Figure 1a , left panels). To test whether merlin can be sumoylated in intact cells, we transfected vector or merlin construct into His-SUMO1 stable transfected F293 cells (Supplementary Figure 1A) and pulled down His-SUMO1-associated proteins with Ni 2 þ beads. Immunoblotting analysis demonstrated that merlin was selectively sumoylated (Figure 1b) . Cotransfection of merlin and SUMO1 displayed similar results (Figure 1c) . Hence, merlin can be sumoylated in vitro and in intact cells. To explore whether merlin is sumoylated in other cell types, we examined endogenous merlin sumoylation under normal growth conditions. When merlin was immunoprecipitated and analyzed using a SUMO1 antibody, we found that endogenous merlin was prominently sumoylated in the majority of cell lines, yet was only modestly in U251 and LN229 GBMs (Figure 1d ). To confirm merlin sumoylation in GBM cells, we knocked down merlin with siRNA and detected sumoylated merlin using anti-merlin antibody-associated immunoprecipitated sample (Supplementary Figure 2) . As merlin has an important role in schwannoma and meningioma development, 32 we collected human schwannoma and meningioma tumor tissues and tested merlin sumoylation status. As shown in Figure 1e , after immunoprecipitation with antimerlin antibody, sumoylated merlin could be readily detected by SUMO1 antibody (upper panel). Reciprocal immunoprecipitation with anti-SUMO1 antibody also demonstrated that merlin was prominently sumoylated in theses samples (Figure 1e, lower panel) . Immunoblotting of the immunoprecipitated proteins indicated that 71-81% of merlin protein in these samples is sumoylated (Supplementary Figure 3) . Collectively, these findings support that merlin can be sumoylated in vitro and in human neoplasms.
K76 residue is the sumoylation site on merlin In exploring the sequence of merlin, we noticed that amino acids 75-78 (LKMD), 363-366 (MKEE), 454-457 (LKQD457) and 542-545 (LKTE) (Figure 2a ) correspond to a consensus sumoylation motif present in numerous SUMO substrates. 28 To determine which residue is a potential sumoylated site, we mutated each of the lysine (K) residues into arginine (R). We co-transfected SUMO1 into HEK293 cells with various merlin constructs. Co-immunoprecipitation assays showed that merlin was potently sumoylated and that the K76R mutation abolished merlin sumoylation (Figure 2b) . Hence, the K76 residue is the major sumoylation site on merlin. To confirm this finding, we transfected F293 cells with various merlin mutants and found wild-type, K364R, K455R and K543R merlins were sumoylated. By contrast, the K76R mutation showed notably reduced sumoylation (Figure 2c ). Thus, these results indicate that K76 is the major sumoylation site on merlin.
Phosphorylation regulates merlin sumoylation As Akt phosphorylates merlin and induces its polyubiquitination and degradation, 25 it is possible that Akt phosphorylation might also regulate its sumoylation. We co-transfected wild-type Akt (Akt-WT), constitutively active mutant (Akt-CA) and kinase-dead mutant (Akt-KD) with GFP-tagged merlin into F293 cells. Ni 2 þ beads pull-down assays showed that overexpression of wild-type Akt or active Akt upregulated the level of sumoylated merlin, whereas kinase-dead mutant Akt decreased merlin sumoylation ( Figure 3a) . P-merlin (S315) signals correlated well with the phosphorylation of the established Akt substrate GSK3, indicating that Akt phosphorylation of merlin regulates its sumoylation. To validate the involvement of Akt signaling in merlin sumoylation, we treated merlin-and SUMO1-co-transfected HEK293 with PI3K/ Akt pathway inhibitors wortmannin and LY294002 following EGF stimulation. EGF treatment increased the merlin sumoylation, as well as the p-Akt (S473) and p-merlin (S315) signals. Wortmannin potently blocked merlin sumoylation and LY294002 reduced EGFtriggered merlin sumoylation (Figure 3b ). To further explore the role of Akt in merlin sumoylation, we transfected merlin variants including wild-type, an unphosphorylated mutant (T230AS315A) and a phosphorylation mimetic merlin (T230DS315D) into F293 cells. Ni 2 þ beads pull-down assay supported that merlin (T230DS315D) was more robustly sumoylated as compared with wild-type control, whereas merlin (T230AS315A) was barely sumoylated (Figure 3c ). Therefore, our data support that Akt phosphorylation of merlin regulates its sumoylation.
Phosphorylation at S518 residue induced by PAK2 kinase has an important role in merlin's tumor-suppressive functions. [33] [34] [35] To test whether S518 phosphorylation is also involved in merlin sumoylation, we first examined sumoylated merlin expression in inducible RT4-D6P2T schwannoma cells overexpressing wild-type, S518A (unphosphorylatable) and S518D (Ser518 mimetic phosphorylation) merlin (Supplementary Figure 1B) . Merlin was sumoylated in S518D cells compared with wild-type (5 4 ) and S518A cells. Interestingly, patient-derived merlin L64P mutant was also robustly phosphorylated and sumoylated (Figure 3d ). To confirm whether merlin sumoylation is also regulated by PAK2 activity, we treated 5 4 cells with PAK2 inhibitor IPA-3 and then examined the sumoylation of merlin. As expected, IPA-3 suppressed merlin sumoylation in a dose-dependent manner, whereas the negative control PIR-3.5 displayed no effect on merlin sumoylation ( Figure 3e ). Moreover, overexpression of PAK2 or constitutively active PAK2 (T402E) upregulated merlin sumoylation compared with control, kinase-dead PAK2 (K278R) or PAK2 (T402A) (Figure 3f ). Therefore, these data support that phosphorylation by Akt or PAK dictates merlin sumoylation.
Sumoylation involves in the regulation of merlin localization Merlin localizes predominantly at the plasma membrane 36, 37 and recent evidence suggests that its physical association with the plasma membrane is important for function. [38] [39] [40] As sumoylation frequently affects target protein subcellular localization, we explored whether merlin sumoylation is required for its membrane localization by transfecting wild-type and various merlin mutants into HER293 cells and monitoring their subcellular location. As expected, wild-type merlin predominantly associated with the plasma membrane, as did K364R, K455R and K543R merlin mutants; in contrast, the K76R mutants show substantial aggregation in the cytoplasm (Figure 4a ). Quantification revealed that B25% of the K76R mutant aggregated inside the cells, instead of the predominant plasma membrane location of wildtype merlin and other mutants (Figure 4b ). Although K76R mutant merlin concentrated inside the cells, it was not localized within the nucleus (Figure 4c ). We observed similar pattern of merlin localization in RT4-D6P2T schwannoma cells transfected wild-type merlin and merlin mutants (data not shown). Therefore, mutating the K76 residue of merlin into R affects its subcellular residency, with merlin sumoylation favoring its membrane localization. SUMO modification frequently recruits target proteins into the nucleus. 41, 42 Recently, Li et al. 26 demonstrated that merlin nuclear translocation has an important role in its tumor-suppressive activity. To determine whether sumoylation directs merlin nucleocytoplasmic trafficking, we examined the biochemical fractionation of merlin stably transfected RT4-D6P2T cells. To eliminate basal merlin phosphorylation signals, we serum-starved the cells overnight, then treated with EGF and finally subjected them to subcellular fractionation. Following serum starvation, EGF treatment increased merlin accumulation in the nucleus (Figure 4d, Supplementary Figure 4A ). The ratio of the nuclear (N) and non-nuclear (C) fraction was enhanced by 2.7-fold compared with vehicle control (Figure 4d ). However, there was no significant change in cells maintained in regular medium with 10% FBS (Figure 4d ). Akt activation was confirmed by immunoblotting for p-Akt (S473) expression. PARP and tubulin were employed as nuclear and cytoplasm markers, respectively (Supplementary Figure 4A) . To confirm the effect of sumoylation on merlin nucleus translocation, we transfected wild-type and K76R mutant merlin into HEK293 cells with or without Flag-SUMO1. Subcellular fractionation showed that wild-type merlin was enriched much more in the nucleus than K76R mutant. SUMO1 co-transfection together with EGF treatment enhanced merlin nuclear accumulation, and Flag-SUMO1 was mainly located in the nuclear fractions (Figure 4e, Supplementary Figure 4B) . Quantification showed that wild-type merlin N/C localization ratio is 2.2-fold greater than the K76R mutant. Overexpression of SUMO1 enhanced the wild-type merlin N/C ratio to 4.8-fold over the K76R mutant, and EGF treatment also increased the ratio to 4.3-fold (Figure 4e) . Hence, sumoylation mediates merlin subcellular localization.
GFP-Merlin
Sumoylation regulates merlin intramolecular and intermolecular interactions To determine whether sumoylation affects merlin intramolecular association, we performed an in vitro binding assay employing purified GST-merlin-CTD (amino acid residues 340-595). The purified recombinant protein was incubated with lysates from HEK293 cells transfected with Myc-merlin-NTD (amino acid residues 1-332) or Myc-merlin (K76R)-NTD. K76R mutation entirely abrogated the binding of merlin CTD to the NTD (Figure 5a ). Expression of Myc-merlin/merlin (K76R)-NTD and purified protein were verified (Figure 5a , middle and bottom panels). To further assess whether sumoylation abolishes the interaction between the N-and C termini of merlin in intact cells, we next performed coimmunoprecipitation assay by transfecting HEK293 cells with Mycmerlin truncate (amino acid residues 133-595) and GST-merlin-NTD or merlin (K76R)-NTD (amino acid residues 1-332). Merlin truncate was pulled down with glutathione beads and the precipitated proteins were analyzed by western blot. Consistent with in vitro binding assay, the GST pull-down experiments demonstrated that K76R mutation abolished the binding by merlin-NTD to its C terminus (Figure 5b ).
PI3K/Akt activity can be inhibited by merlin through its binding to Akt and PIKE-L. 13, 25 To gain insight into the mechanism by which sumoylation is required for the tumor-suppressive activity, we introduced wild-type merlin or unsumoylated mutant into HEK293 cells and examined Akt activation signals. In contrast to vector control, wild-type merlin overexpression reduced the levels of p-Akt (S473), as well as downstream signaling of Akt (Figure 5c ). However, merlin K76R mutant failed to suppress Akt signaling, indicating that unsumoylated merlin was unable to block PI3K/Akt signaling to exert the tumor suppression activity. As merlin exerts its inhibitory activity by directly interacting with Akt, we employed an in vitro binding assay to investigate the impact of sumoylation on merlin's binding activity. As shown in Figure 5d , the K76R mutant displayed weaker binding affinity to Akt than wild-type merlin. To confirm the binding activity between Akt and wildtype or K76R mutant merlin, HEK293 cells were transfected with GST-Akt and GFP-tagged wild-type or K76R merlin, and GST-pulldown samples were analyzed by immunoblotting with anti-GFP antibody. The association between Akt and K76R merlin was much less than that with wild-type merlin ( Figure 5e ). As merlin inhibits PI3K through binding to PIKE-L, 13 we further examined whether the binding between PIKE-L and merlin was affected by sumoylation. Strikingly, K76R mutant was unable to bind PIKE-L (Figure 5f ). Together, these data indicated that SUMO modification can regulate merlin intramolecular and intermolecular association and that sumoylation is essential for the inhibitory effect of merlin on PIKE/PI3K/Akt signaling.
Cell density regulates merlin sumoylation As merlin mediates contact-dependent inhibition of proliferation, 43 we examined whether cell density regulates merlin sumoylation. We cultured schwannoma cells with stably transfected merlin (5 4 ) and collected the cells at different densities. Immunoprecipitation with anti-merlin antibody showed that at 50% density, merlin was markedly sumoylated, whereas at 100% density, sumoylated merlin was hardly detected (Figure 6a, right panels) . Accordingly, merlin was phosphorylated by Akt on S315 at low density, in alignment with Akt activation status (Figure 6a , left panels) and supporting the finding that Akt phosphorylation is involved in merlin sumoylation. Consistently, in schwannoma cells that overexpressed merlin (S518D), the sumoylated form was highly expressed at both 50 and 100% confluent densities (Figure 6b ). By contrast, merlin (S518A) sumoylation was hard to be detected regardless of cell density (Figure 6c ). However, merlin sumoylation was stronger in 50% density cells than that in confluent cells. To examine the regulation of endogenous merlin sumoylation by cell density, we collected MEF cells at different densities. Immunoprecipitation with anti-merlin antibody showed that merlin sumoylation was upregulated as cell density increased (Figure 6d, left upper panel) . By contrast, in Akt-null MEF cells, although merlin expression was increased as the cell density escalated, merlin sumoylation was not enhanced compared with the wild-type counterpart (Figure 6d, right panel) , supporting that Akt phosphorylation of merlin might be essential for merlin sumoylation. Notably, we found that both Akt and merlin phosphorylation of S315 were decreased as cell density increased in wild-type MEF cells (Figure 6d, left 3rd and 4th panels) . Nonetheless, p-merlin (S518) was upregulated as the cell density increased in both wild-type and Akt-null MEF cells, and the signals in Akt-null cells were more robust in Akt-null than in wild-type cells (Figure 6d, 5th panel) . The inconsistency of the cell density sumoylation between merlin (5 4 ) (Figure 6a ) and MEF (Figure 6d ) cells might be caused by whether Akt phosphorylation on S315 or PAK phosphorylation on S518 has a dominant role in mediating merlin sumoylation. Collectively, these data indicated that merlin sumoylation was regulated by cell density and merlin phosphorylation status by PAK or Akt, which is potentially responsible for the contact-dependent inhibitory activity of merlin.
Sumoylation regulates merlin tumor suppressor activity To examine the effect of sumoylation on inhibition of cell proliferation by merlin, we transfected vector, wild-type merlin or mutants into HEK293 cells and monitored cell proliferation using an MTT assay. Compared with vector control, ectopic expression of merlin decreased cell proliferation by 50%, as did the merlin mutants (K364R, K455R and K543R) (Figure 7a ). By contrast, merlin K76R failed to suppress cell proliferation (Po0.01). We made a similar observation with RT4-D6P2T schwannoma cells (Figure 7a) . To examine the effect of sumoylation of merlin on cell migration and invasion, we conducted wound-healing assays to examine cell migration of RT4-D6P2T cells transfected with wildtype merlin or unsumoylated mutants. As shown in Figure 7b , compared with vector control, wild-type merlin suppressed cell migration. By contrast, K76R mutant was unable to inhibit cell migration. As shown in Figure 7c , merlin significantly inhibited RT4-D6P2T cell invasion compared with control (Po0.05). K76R mutation attenuated the invasion-suppressive activity on invasion by merlin. Together, these results support the notion that sumoylation is required for the tumor-suppressive activity of merlin.
It has been previously shown that wild-type merlin dramatically inhibits subcutaneous growth of U87MG glioma cells. 44 To further evaluate the effect of sumoylation on tumor-suppressive activity of merlin in vivo, we inoculated stably transfected merlin or merlin (K76R) U87MG cells in nude mice. Both wild-type merlin and K76R mutant merlin dramatically inhibited subcutaneous growth of the glioma cells. However, the subcutaneous tumor growth experiments also showed that tumor volume and tumor weight in K76R mutant merlin-expressing U87MG cells were much greater than the wild-type merlin-transfected cells (Figures 7d and e) , indicating that K76R attenuates tumor-suppressive activity in vivo. To determine the cellular mechanism underlying this effect, Aktmediated merlin phosphorylation and degradation were detected in the tumor tissues. We observed that both Akt and merlin phosphorylation was increased in K76R mutant merlin cells compared with wild-type merlin-expressing cells (Figure 7f) . It was interesting to note that expression of K76R merlin was lower than that of wild-type merlin in vivo (Figure 7f, left top panel) . Immunoprecipitation assays showed that K76R mutant was more prominently polyubiquitinated than wild-type merlin (Figure 7f , right panel), indicating that sumoylation might regulate merlin expression level and stability, as this property has been previously described. 45, 46 To explore this possibility, we transfected wild-type or unsumoylated mutant (K76R) merlin with or without SUMO1 into HEK293 cells. Cells were then treated with the protein translation inhibitor cycloheximide for various time points. In the absence of exogenous SUMO1, wild-type merlin half-life (t 1/2 ) was B4-6 h and co-transfection of SUMO1 markedly increased its stability (Supplementary Figure 2, upper three panels) . By contrast, merlin K76R possessed t 1/2 of B2 h, and it was almost completely degraded at 10 h regardless of SUMO1 expression level (Supplementary Figure 2, lower three panels) , supporting that sumoylation may contribute to the stability of merlin. Collectively, these data demonstrate that sumoylation is involved in regulating merlin tumor suppressor activity.
DISCUSSION
Sumoylation is known to regulate the subcellular localization, stability and protein-protein interaction of target proteins, 32 mostly described for nuclear and perinuclear proteins but also for other cell surface proteins such as ion channels, 47 glutamate and kainate receptors. 48 In addition to finding that the K76 residue is the sumoylated site modified by SUMO1, we observe that sumoylation regulates merlin's protein stability (Supplementary Figure 5 and Figure 7F ), subcellular localization ( Figure 4 ) and tumor-suppressive activities (Figure 7 ). For merlin's tumor suppressor activity, as shown in Figure 2 , both in vitro and in vivo data indicated that mutation of the sumoylation site of merlin, K76, impaired its tumor-inhibitive function, however, K76R cannot completely inhibited merlin's tumor suppressor activity. MST1/2 are the key components of Hippo signaling pathway, which can be regulated by merlin. 49, 50 Recently, it is reported that merlin can enhance MST1/2 activity in melanoma cells. 51 Based on this, we found that overexpression of merlin increased phosphorylation of MST1/2 in HEK293 cells, consistent with the previous reports; however, the K76R mutation did not affect merlin's function on regulating MST1/2 activity (Supplementary Figure 6 ). These data indicate that the K76R mutation did not cause the misfolding of merlin, indicating that sumoylation is involved in merlin's tumor suppressor function.
The molecular mechanisms by which merlin functions as a tumor suppressor remain incompletely understood. Accumulative studies reveal that numerous regulatory mechanisms may contribute to merlin's tumor-suppressive activities including post-translational modification, 23, 25, 26 intramolecular and intermolecular association, 17, 21 cortical cytoskeleton and nuclear localization, 11 and related signaling regulation. 26 It has been previously shown that merlin exerts its tumor-suppressive activity both in cell cortex and the nucleus. In the present study, with the observations using GFP-fusion proteins, we found that the unsumoylated merlin resides mainly in the cytoplasm as compared with the plasma membrane localization of the wildtype, sumoylated merlin (Figures 4a and b) . Subcellular fractionation analysis reveals that merlin localizes in the nucleus and overexpression of SUMO1 facilitates merlin nuclear accumulation. Nonetheless, K76R mutation abolishes merlin nuclear accumulation regardless of SUMO1 expression levels (Figures 4d and e) .
Collectively, these finding demonstrate that the K76R mutant fails to locate either to the cell cortex or to the nucleus to exert its normal functions, suggesting that sumoylation is required for merlin's tumor-suppressive activity.
The mechanism through which SUMO modification affects merlin nucleocytoplasmic shuttling remains unknown. Merlin contains an FERM domain shared by several cytoskeletal molecules including band 4.1 proteins. It does not contain a classical importin nuclear localization sequence but has a motif in C terminus that promotes export via the CRM1-exportin pathway. 52 Several band 4.1 proteins are targeted to the nucleus by nuclear localization signal, which is a stretch of basic residues (KKKR) that bind to a negatively charged motif of importin. 53 Merlin N terminus contains an analogous stretch of basic residues (309RRRK312), which may be involved in its nuclear targeting. 54 It is also reported that normal membrane localization and actin association of merlin are dependent on folding of its N-terminal domain. 55 Moreover, according to Kressel and Schmucher 52 , merlin exon 2 has a cytoplasmic retention signal, which keeps merlin in the cytoplasm. Interestingly, the merlin sumoylation site K76 is also located in exon 2 and sumoylation is able to regulate Sumoylation regulates merlin function Q Qi et al binding properties and provides a platform for association with other molecules. 27 It is possible that SUMO modification can affect the structure of the merlin and recruit other molecules to exert the nuclear-importing activity or shield the cytoplasmic retention signal.
Post-translational modifications such as phosphorylation, ubiquitination and sumoylation have an important role in protein function, and the cross-talk among these post-translational modifications is complex. It has been demonstrated that kinaseinduced phosphorylation regulates target protein sumoylation, including the examples of PKC phosphorylation regulating GluK2 sumoylation 56 and MAPK-induced Ser727 phosphorylation promoting sumoylation of STAT1.
57 PI3K/Akt pathway has an important role in merlin stability and function. In the present study, we show that Akt phosphorylation is required for merlin sumoylation ( Figure 4) . We have demonstrated that T230 and S315 residues are the phosphorylation sites of Akt. 25 It is interesting to note that these sites are very close to the proposed nuclear localization signal basic residues (309RRRK312). 54 Further investigation showed that the unsumoylated form of merlin lost the activity to inhibit Akt signaling (Figure 5c ). On one hand, sumoylation contributes to merlin tumorigenesis activity via inhibiting PI3K/Akt pathway and on the other hand, perhaps there is a feed-back loop between merlin and Akt, which might have an important role for tumor progression. One of the more rapidly expanding fields in cell signaling is the characterization of proteins conjugated to Ub (ubiquitin) or Ub-like peptides such as SUMO as well as the cross-talk between them. For example, SUMO1 modification of IkB inhibits NF-kB activation by acting antagonistically to generate proteins resistant to ubiquitination-induced degradation. 58 Further, arsenic degrades PML through a sumoylation-dependent ubiquitin-mediated pathway. 59 As Akt phosphorylation can trigger merlin ubiquitination, 25 it becomes necessary to examine the relationship between merlin sumoylation and ubiquitination. To provoke Akt signaling, we employed EGF stimulation. Our results demonstrated that both wild-type and unsumoylated merlin can be ubiquitinated (Supplementary Figure 7A) . EGF treatment strongly promoted merlin ubiquitination in HEK293 cells at 10 min, which then decreased and returned to baseline by 60 min (Supplementary Figure 7B, 2nd panel) . However, merlin sumoylation was steadily enhanced after a 10-min treatment with EGF. This pattern was also confirmed in the inducible merlin stably transfected RT4 schwannoma cells (Supplementary Figure 7C) . Thus, EGF regulates merlin sumoylation as well as polyubiquitination, and it appears that polyubiquitination is independent of merlin sumoylation.
Previously, merlin was considered to be a cytoskeletonassociated protein functioning as a tumor suppressor. However, many lines of evidence indicate that merlin functions in various subcellular compartments including the plasma membrane, cytoplasm and nucleus. 39 Merlin's unique tumor suppressor activity is believed to be associated with the action of the headto-tail 'closed' conformation in the cytoplasm. However, more recently, merlin has been shown to regulate trafficking and retention of mitogenic and adhesion receptors on the cell surface and the degradation of nuclear proteins. 60 It is also reported that merlin controls growth in its 'opened' conformation and phosphorylation on merlin at S518 site induces it to a 'closed 'conformation. 61 These observations created confusion about merlin's mechanism of tumor suppression, which indicates that merlin functions through a complex signaling system. In Figure 5 , the data showed that merlin sumoylation is involved in its intermolecular and intramolecular association. The K76R mutant decreased the intramolecular binding of merlin (Figures 5a and b) , indicating that merlin sumoylation is need for the 'closed' form of merlin, which is in favor of the nuclear localization for merlin function through E3 ubiquitin ligase CRL4 DCAF1 inhibition. In addition, as shown in Figures 5d, e, and f, K76R mutant suppressed the intermolecular binding of merlin with Akt and PIKE-L, leading to the abolishment of merlin function on PI3K/Akt signaling, which is consistent with Akt activity enhancement and tumor cell proliferation shown in Figures 5c and 6d , respectively. Therefore, merlin sumoylation is involved in merlin's tumor suppressor function in spite of its self-association status. It remains unknown how merlin is sumoylated. The precise SUMO E3 ligase required for merlin sumoylation has not been described and the mechanism by which sumoylation regulates nucleocytoplasmic shuttling is unknown. Our evidence demonstrates that Akt or PAK has an essential role in triggering merlin sumoylation. Interestingly, it has previously been shown that Akt-mediated phosphorylation can regulate SUMO E3 ligase. 62, 63 Conceivably, Akt is the key factor regulating the dynamic process of sumoylation and de-sumoylation.
Taken together, in this study, our findings add sumoylation to the list of post-translational molecular mechanisms that regulate the trafficking and signaling of merlin and provide several lines of evidence to support the notion that sumoylation is required for the biological properties and tumor-suppressive functions of merlin. A future challenge is to study the interplay between these mechanisms and to unravel the physiological context in which they control merlin functions in health and disease. Furthermore, our discovery of the sumoylation of merlin and its potential effects on tumorigenesis may provide a better understanding of the unique actions of this protein and may be valuable for the development of new therapeutic strategies.
MATERIALS AND METHODS
See supplementary materials.
